UnitedHealth Maintains Status Quo On Vytorin For Now, But CIGNA Revises Step Therapy Policy
This article was originally published in The Pink Sheet Daily
Executive Summary
ENHANCE data reveals no safety issues that require immediate change, United says
You may also be interested in...
ACC Meeting ENHANCE Panel Calls For Return To Statins
The failed atherosclerosis study provides “no new evidence to support the use of this drug,” a cardiology panel says.
Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs
The agency’s projection that Medicare will spend $3.5bn on Leqembi in 2025 is nearly three times the level of sales that marketer Eisai is expecting for the drug in North and South America combined in its fiscal year 2026.
Biosimilar Substitution In Medicare Part D Formularies Mid-Year Established In Final Rule
Policy may be helpful in promoting acceptance of follow-ons in Medicare but is not expected to result in near-term savings to the program.